Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?

Enrico Carmina, M.D.,a Anna Maria Campagna, M.D.,a Pasquale Mansuet, M.D.,b Giustina Vitale, M.D.,b Daniel Kort, M.D.,c and Roger Lobo, M.D.c

a Department of Medical and Biological Sciences and b Department of Clinical Medicine, University of Palermo, Palermo, Italy; and c Department of Obstetrics and Gynecology, Columbia University, New York, New York

Objective: To determine possible prediction of regular menses with aging in anovulatory women with polycystic ovary syndrome (PCOS).

Design: Cohort.

Setting: Academic practice.

Patient(s): A total of 54 anovulatory women with PCOS and 28 age- and weight-matched control subjects.

Intervention(s): Blood and ovarian ultrasound at baseline and after 5 years.

Major Outcome Measure(s): Serum antimüllerian hormone (AMH), gonadotropins, androgens, insulin sensitivity, and ovarian ultrasound.

Result(s): After 5 years, there was a significant decrease in AMH in women with PCOS and control subjects (10 of 54 anovulatory women became ovulatory after 5 years). There was a significant negative correlation between baseline serum AMH and ovulatory function after 5 years. However, baseline serum AMH ≥4 ng/mL was associated with ovulatory function.

Conclusion(s): Serum AMH may help predict ovulatory function with aging in anovulatory women with PCOS. (Fertil Steril 2012;98:1043–6. ©2012 by American Society for Reproductive Medicine.)

Key Words: PCOS, ovulation, AMA, aging

Discuss: You can discuss this article with its authors and with other ASRM members at http://fertstertforum.com/carminae-amh-ovulatory-function-polycystic-ovary-syndrome-aging/

Several studies have suggested that many of the symptoms and signs of polycystic ovary syndrome (PCOS) may improve with aging (1–4). Indeed, a proportion of women with PCOS, previously with irregular menses, may become more regular and ovulate during late adulthood. In our long-term longitudinal study of 193 women with PCOS, about 30% of women had improved symptoms and signs by their mid-40s, and ~10% could no longer be diagnosed as having PCOS by established criteria. Another 20% of women had normal menses and ovulatory function, but still met the criteria for the diagnosis of PCOS by the Rotterdam criteria (4).

These findings are at least in part due to the decline in ovarian and adrenal androgens that occur in both normal women and those with PCOS as they move from the third to the fifth decade of life. In normal women, ovarian androgen responses to hCG begin to decline at the age of 30 years (5) and a marked decrease in adrenal androgen secretion takes place between the second and fifth decades (6). Also, ovarian size has been shown to decrease with aging (7, 8).

In PCOS, some studies have shown that both total and non–SHBG-bound testosterone is ~50% lower at 45–47 years compared with the levels found in patients in their 20s and 30s (9). Similarly, older patients with PCOS have lower adrenal androgen levels and smaller ovaries compared with young women with PCOS (2, 9, 10). In our longitudinal study, a decrease of...
testosterone levels of ~25% and of DHEAS of ~30% was observed in 193 women with PCOS who were followed from a mean age of 22 years to a mean age of 43 years (4). Ovarian size was also reduced, with the mean ovarian size decreasing by ~20% (from 10.9 to 9.1 mL) (4).

Previous work has suggested that the regularity of menstrual cycles with aging in women with PCOS may be related to a smaller follicle cohort size in those women (11). However, it has not been determined if any parameters may be useful in helping to predict those women who will attain regular cycles among the general population of women with PCOS who have irregular cycles. Here we sought to determine if any parameters may be helpful in this regard in a prospective cohort of women with PCOS followed for 5 years. We focused our attention on changes in levels of serum antimullerian hormone (AMH), because it relates well to the size of the total follicular cohort of the ovary.

MATERIALS AND METHODS

In this prospective study, 54 anovulatory hyperandrogenic women with PCOS aged 35–39 years (mean 37 ± 1 years) were evaluated. The diagnosis of PCOS was made according to Rotterdam criteria (12). The women had been treated previously with various therapies for menstrual irregularity (oligomenorrhea or amenorrhea) and/or hyperandrogenism (acne or hirsutism) but had not received any treatment for menstrual cycles with aging in women with PCOS may be related to a smaller follicle cohort size in those women (11). However, it has not been determined if any parameters may be useful in helping to predict those women who will attain regular cycles among the general population of women with PCOS who have irregular cycles. Here we sought to determine if any parameters may be helpful in this regard in a prospective cohort of women with PCOS followed for 5 years. We focused our attention on changes in levels of serum antimullerian hormone (AMH), because it relates well to the size of the total follicular cohort of the ovary.

In all patients and control subjects, ovarian morphology was assessed by pelvic ultrasound. Ovarian size was determined, as was the presence, size, and number of ovarian follicles 2–10 mm. The presence of polycystic ovaries was established by the presence of ten or more peripherally oriented cystic structures in one ultrasonographic plane, each of which measured 2–10 mm in diameter, arranged around a dense stroma (17, 18). Ovarian volume was calculated by the formula π/6 (D1 × D2 × D3) where the dimensions (D) of length, width, and thickness were used. The size of both ovaries was assessed and mean ovarian size was calculated. According to our data in normal women, increased ovarian size was defined as a mean ovarian size >7.5 mL (19).

The adopted procedures were in agreement with the Helsinki Declaration of 1975, and the study was approved by the local Ethics Council of Palermo University. All subjects gave their informed consents to participate in the study.

Statistical Analysis

Group means were compared with the use of analysis of variance with post hoc evaluation by the method of least squares and by pairwise means comparisons (after log transformation of the values). Pearson test was used for correlations. All data are presented as mean ± SD.

RESULTS

At the initial evaluation (Table 1) women with PCOS had a body mass index (BMI; 28.2 ± 3 kg/m²) similar to, and levels of circulating LH, LH/FSH ratio, T, DHEAS, insulin, and AMH higher than matched control subjects of similar age. Insulin sensitivity calculated by QUICKI was lower. Women with PCOS also had increased ovarian volume (10.2 ± 2.7 vs. 4.8 ± 1.1 mL; P<.01). The same parameters were still...
significantly increased in PCOS women compared with control subjects when evaluated after 5 years (Table 1).

Comparing the values at the second evaluation with the initial levels (5 years before) in both PCOS and control subjects, a significant decrease of AMH was observed (Fig. 1), whereas the values of T and DHEAS decreased significantly (P < .01) only in women with PCOS (data not shown). No significant changes in BMI, LH, LH/FSH ratio, insulin, QUICKI, and ovarian size were observed. Interestingly, the mean decrease in AMH was similar in women with PCOS (40 ± 12%) and control subjects (41 ± 10%).

The women with PCOS who were ovulatory after 5 years had lower serum LH, T, and AMH than the anovulatory group, but the differences were significant only for AMH values (2.4 ± 0.8 vs. 4.3 ± 0.90 ng/mL; P < .01). However, the ovari- latory group of women with PCOS still had higher AMH values compared with values in the normal aging control sub- jects (1.0 ± 0.7 ng/mL; P < .01). Over the 5 years, there was no significant change in ovarian size, BMI, or insulin sensitivity.

Presence of ovulation (evaluated by P levels) after 5 years, at the mean age of 42 years, did not correlate with BMI or any initial hormonal parameter at the age of 37 years, with the exception of AMH values (r = −0.42; P < .05), suggesting that a lower AMH level is associated with the chance of ovulatory function. In line with this, patients who became ovulatory with aging had significantly lower levels of AMH at their ini- tial evaluation (anovulatory patients who became ovulatory: 4.8 ± 1.7 ng/mL; vs. anovulatory patients who remained anovulatory: 7.1 ± 2 ng/mL; P < .01). After 5 years, the ovulatory group had mean values of 2.4 ± 0.8 ng/mL, which re- mained significantly lower than the anovulatory group at the same time point: 4.3 ± 0.9 ng/mL (P < .01; Fig. 1).

Evaluating absolute values, we did not find a clear pre- dictive value of AMH for ovulatory function, but women with PCOS having AMH values <5 ng/mL had a 60% probability to ovulate by age 42, and all women having values ≤4 ng/mL had ovulatory function. None of the women who remained anovulatory had initial values of AMH <4 ng/mL. The complete range of values in the ovulatory group was 3.1–8.0 ng/mL initially and 1.8–3.3 ng/mL after 5 years. Corresponding complete ranges in the anovulatory group were 4.1–12 ng/mL initially and 2.9–7.3 ng/mL after 5 years.

### DISCUSSION

In this study we assessed the endocrine profile of a group of women with PCOS women aged 35–40 years who were reevaluated after 5 years. The aim of this study was to under- stand whether any hormonal or ovarian parameter may be helpful in determining menstrual patterns and ovulatory function as the disorder evolves with aging. It has been de- scribed previously that with aging, women with PCOS show a significant improvement in their endocrine profiles and that this may be associated with the observation of more nor- mal menses and ovulatory cycles (1–4). However, only a proportion of patients normalize their menses and resume ovulatory cycles.

In the present study, 10 anovulatory patients out of 54 (~20%) became ovulatory at a mean age of 42 years with a prevalence of improvement that was similar to what we ob- served previously (4). Here we showed that ovulation ap- peared in women with PCOS who had lower values of AMH values 5 years earlier. Although AMH levels correlated with serum T and insulin, no significant correlation was found be- tween changes in these hormonal parameters and ovulatory function. Also in the 5 years of follow-up, we did not observe changes in ovarian size, BMI, or insulin sensitivity. Clearly we would expect to see such changes with a longer follow-up, as has been described previously (4). Although the present num- bers are small, with only 20% of the women having ovulatory function at 5 years, the data suggest that a critical level of se- rum AMH is ~4 ng/mL. None of the group that remained anovulatory had values below that value at their initial evaluation.

---

### TABLE 1

<table>
<thead>
<tr>
<th>Age, y</th>
<th>BMI, kg/m²</th>
<th>LH, mUI/mL</th>
<th>LH/FSH ratio</th>
<th>T, ng/dL</th>
<th>DHEAS, μg/mL</th>
<th>AMH, ng/mL</th>
<th>IRI, μU/mL</th>
<th>QUICKI</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCOS 37 ± 1</td>
<td>28 ± 6</td>
<td>10 ± 3.7</td>
<td>1.6 ± 0.7</td>
<td>74 ± 22</td>
<td>2.4 ± 1</td>
<td>6.7 ± 2.1</td>
<td>15.1 ± 6.5</td>
<td>0.325 ± 0.02</td>
</tr>
<tr>
<td>Control 37 ± 1</td>
<td>27.4 ± 3</td>
<td>6.4 ± 1.4</td>
<td>1.1 ± 0.2</td>
<td>28 ± 11</td>
<td>1.8 ± 1</td>
<td>1.7 ± 0.7</td>
<td>9.4 ± 2</td>
<td>0.355 ± 0.02</td>
</tr>
<tr>
<td>PCOS 42 ± 1</td>
<td>28 ± 6</td>
<td>8.8 ± 4</td>
<td>1.5 ± 0.7</td>
<td>58 ± 19</td>
<td>2.2 ± 1.2</td>
<td>3.9 ± 1.2</td>
<td>14 ± 4</td>
<td>0.325 ± 0.02</td>
</tr>
<tr>
<td>Control 42 ± 1</td>
<td>28 ± 4</td>
<td>6.5 ± 1.1</td>
<td>1 ± 0.3</td>
<td>25 ± 16</td>
<td>1.7 ± 1</td>
<td>1 ± 0.7</td>
<td>9.5 ± 2.4</td>
<td>0.351 ± 0.02</td>
</tr>
</tbody>
</table>

Note: AMH = antimi⁠-⁠lierran hormone; BMI = body mass index; IRI = immunoreactive insulin; PCOS = polycystic ovary syndrome; QUICKI = quantitative insulin sensitivity check index.


---

### FIGURE 1

Bar graph of values of antimüllarian hormone (AMH) before and 5 years after in anovulatory and ovulatory group and control subjects. PCOS = polycystic ovary syndrome. ** P < .01 vs. control and PCOS becoming ovulatory. * P < .01 vs. control. Carmina. AMH and normalization of menses in PCOS. Fertil Steril 2012.
One of the potential concerns in these data is that the assays for AMH were carried out with reagents from different manufacturers, although we have been reassured that in this instance, the assays are the same, and this occurred merely due to a commercial acquisition. Moreover even if values are slightly higher or lower between the assays in the two time periods, it would have affected the subgroups in the same way; and although absolute values and cutoff points may not be precise, the trends, and therefore our conclusions, are expected not to be different. It should also be noted that in our previous study of a 20-year follow-up period [4], other parameters, such as T, were observed to decrease, which was not the case here with only 5 years of observation. Our observations of excursions in AMH and menstrual function are more appropriate with the shorter follow-up, in that a longer follow-up puts many women into perimenopause or beyond.

It is well known that AMH levels are higher in women with PCOS compared with normal control subjects of similar age [20–24] and that among women with various phenotypes of PCOS, the anovulatory group of women have the highest AMH values [22]. In addition, in PCOS, serum levels of AMH generally correlate with serum androgens and with insulin [21–23], which also relate to the more severe phenotypes. Finally, earlier studies have found that increased AMH levels in PCOS are not only correlated with the increased number of small preantral follicles, but also to some intrinsic abnormality of granulosa cell function [24]. These findings may signify that in some way, AMH levels express the severity of the disorder probably reflecting the severity of derangement in folliculogenesis [24]. Also, these data are similar but different from other data that in women undergoing laparoscopic ovarian diathermy, the women data are similar but different from other data that in women with PCOS who achieve regular menstrual function may provide some useful clinical information in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod 2009;24:2760–65.


Amer SA, Li TC, Ledger WL. The value of measuring anti-mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod 2009;24:2760–6.

REFERENCES


